Risk factors for positive margin in breast conservative surgery for localized breast cancer

James Ferrick DO¹, Hina Zubair MD¹, Sumeet Salvi OMS-IV², Elaine A Davis RN, MS, EdD¹, Christine A Welch MS¹, Amir S Kamran MD, MS³

 ¹ CAMC Institute for Academic Medicine, Charleston, WV
 ² West Virginia School of Osteopathic Medicine, Lewisburg, WV
 ³ Department of Oncology, Charleston Area Medical Center, Charleston, WV







• To investigate factors associated with positive margins in breast cancer patients undergoing breast-conserving surgery for invasive localized breast cancer.





Background





Breast Cancer

- A major global concern due to high incidence and prevalence
 - In 2022, there were 2.3 million diagnoses and 670,000 deaths globally
 - In the US alone, incidence of female breast cancer is expected to be 310,720 with an additional 2,800 cases in men for the year 2024
 - Accounts for 30% of newly diagnosed female cancers with a lifetime incidence of 1/8 in women
- Improved mortality and morbidity
 - 5-year relative survival rates (SEER)
 - Localized breast cancer 99%
 - Distant breast cancer 31%
 - All types/stages of breast cancer 91%







Breast-conservative Surgery

- The removal of breast tumor tissue (invasive or in situ) surrounded by a margin of normal tissue
- Candidates typically have early-stage (stage 1 or 2) breast cancer, or DCIS, which is isolated to one area of the breast
- Neoadjuvant chemotherapy (option for larger tumors)
- Followed by adjuvant radiotherapy to tumor bed + surrounding tissue
- Procedures included:
 - Lumpectomy, partial mastectomy, wide excision, segmental mastectomy





Surgical Margins

- Negative margins
 - Necessary to avoid any breast cancer recurrence
 - Defined as no gross or microscopic disease evident at the resection border, also known as "no tumor on ink"
- Positive margins
 - Patients need additional surgeries with larger margins, or total mastectomy
 - Exposes patients to greater morbidity
 - Risk of surgical complications
 - Delays the start of adjuvant therapy
 - Worsened cosmetic appearance





Methods





Study Design

- Retrospective cohort study
- Patients identified using CAMC Cancer Registry
- Queried from 2009-2022 for females diagnosed with invasive breast cancer who had surgery for localized disease





Study Design

- Inclusion Criteria:
 - Female breast cancer patients
 - Breast-conserving surgery performed at CAMC
 - Histology demonstrating invasive breast cancer





Study Design

- Exclusion Criteria:
 - Male breast cancer patients
 - Biopsy only: mammotome, core needle, FNA, excisional biopsy
 - Total mastectomy (any type)
 - Histology demonstrating non-invasive breast cancer
 - Patients with history of prior malignancy
 - Lymph node positive disease
 - Metastatic disease





Sample

- 5286 records of breast cancer patients were obtained from the CAMC Cancer Registry
- 1041 patients remained after applying inclusion and exclusion criteria



Variables

- Comorbidities
 - BMI, hypertension (HTN), hypothyroidism, diabetes, coronary artery disease (CAD), osteoporosis, cardiac arrhythmia, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular accident (CVA), valvular disease, venous thromboembolism (VTE), congestive heart failure (CHF)
- Risk Factors
 - Tobacco use, hormone replacement therapy (HRT) use
- Tumor characteristics
 - Tumor size, laterality, breast location, stage (clinical/pathological)
- Histology
 - Histology type, multifocality, grade, Ki67
- Receptor status
 - ER, PR, HER2/neu





Statistical Tests

- SAS 9.4 was utilized to process the data for this investigation.
- Descriptive variables:
 - Means \pm standard deviation(SD) for continuous variables
 - Proportions (%) for categorical variables.
- Univariate analysis:
 - Mantel-Haenszel Chi-Square, Chi-square or Fishers Exact, students T-test, Kaplan Meier method
- Multivariate analysis:
 - Logistic regression (backwards selection), and Cox proportional hazards model.





Results







Results

Variable	Negative Margins (mean ± SD)	Positive Margins (mean ± (SD)	P value
Age	64.1 ± 10.5	63.3 ± 12.2	.52
BMI	31.6 ± 7.4	30.5 ± 7.5	.15

Comorbidities

Variable	Negative Margins (%)	Positive Margins (%)	P value
Hypertension	65.5%	61.1%	.37
Tobacco	32.6%	28.7%	.41
Tobacco (last 30 days)	14.6%	13.0%	.65
Hypothyroid	27.8%	30.6%	.54
Diabetes	21.5%	17.8%	.34
HRT	13.0%	19.4%	.07
CAD	12.2%	12.0%	.96
Osteoporosis	10.9%	8.4%	.42

Comorbidities

Variable	Negative Margins (%)	Positive Margins (%)	P value
Arrhythmia	7.5%	13.0%	.05
COPD	8.7%	4.6%	.15
CKD	5.7%	5.6%	.96
CVA	5.3%	2.8%	.26
Valvular disease	5.2%	3.7%	.51
VTE	2.8%	.93%	.25
CHF	2.7%	1.9%	.61

Tumor Size (cm)



Size Staging Category	Negative Margins	Positive Margins	P value
< 2 cm	78.7%	57.4%	
2 to 5 cm	20.7%	38.9%	P < .0001
> 5 cm	.5%	3.7%	

Ki-67

Negative Margins Positive Margins		26.0 ± 22 27.1 ± 21				
				P = .6	<u>-</u>	
-	1					
0	10	20	30	40	50	60

Variable	Negative Margins (%)	Positive Margins (%)	P value
Ki-67: >15.5	57.8%	60.2%	.64

Tumor Characteristics (Location)

Variable	Negative Margins (%)	Positive Margins (%)	P value
Laterality (left)	53.0%	51.9%	.82
	Location (specific)		
12 o'clock	12.9%	15.7%	
3 o'clock left, 9 o'clock right	6.5%	4.6%	
3 o'clock right, 9 o'clock left	4.4%	4.6%	
6 o'clock	2.9%	6.5%	.047
LIQ	7.3%	6.5%	
LOQ	7.6%	8.3%	
UIQ	17.3%	13.0%	
UOQ	38.1%	38.0%	
Retroareolar	2.5%	2.8%	
Multiple locations	.5%	0%	

Tumor Characteristics (Histology)

Variable	Negative Margins (%)	Positive Margins (%)	P value
Ductal	86.2%	74.1%	.001
Lobular	7.2%	20.4%	<.001
Mucinous	3.2%	2.8%	
Microinvasive	0	.9%	
Other	.9%	.9%	
Ductal and lobular	.8%	.9%	
Tubular	.9%	0%	

Tumor Characteristics (Grade)

Variable	Negative Margins (%)	Positive Margins (%)	P value
	Grade		
Grade 1	26.1%	21.3%	
Grade 2	45.0%	48.2%	.56
Grade 3	28.9%	20.6%	
	Stage		
IA	79.4%	61.1%	
IB	2.5%	3.7%	< .0001
IIA	17.6%	34.5%	
IIB	.5%	3.7%	

Tumor Characteristics

Variable	Negative Margins (%)	Positive Margins (%)	P value		
Multiple tumors / One primary (Multifocality)	4.5%	17.8%	< .0001		
	Receptor Status				
ER (positive)	87.5%	88.0%	.88		
PR (positive)	79.4%	84.3%	.23		
HER2/neu (negative)	91.9%	87.0%	.22		
Triple Negative (yes)	10.2%	9.3%	.76		

Logistic Regression to Predict Positive Margin

Variable	Odd Ratio	95% Confidence Interval	P value
Stage	1.6	1.3-2.0	< .0001
Multifocality	4.2	2.3-7.8	< .0001
Lobular histology	2.7	1.6-4.7	.0005
6 o'clock position	2.6	1.0-6.4	.04





Logistic Regression to Predict Recurrence

Variable	Odd Ratio	95% Confidence Interval	P value
Ki-67 > 15.5	4.5	1.5-13.2	.006
Positive Margin	2.8	1.2-6.4	.018
PR (negative)	2.9	1.4-5.8	.003





Cox Proportional Hazards Model for Overall Survival

Variable	Hazard Ratio	95% Confidence Interval	P value
Recurrence	4.9	3.0-7.8	< .0001
Age ≥ 80	3.8	2.5-5.7	< .0001

Discussion





Significant Findings

- Associated with positive margins
 - Arrhythmia
 - Tumor size (mean + categorical)
 - 6 o'clock position
 - Invasive ductal histology
 - Invasive lobular histology
 - Stage
 - Multifocality
 - Recurrence, local/distant







Multifocal

Multicentric



https://radiologykey.com/wp-content/uploads/2016/09/A318601_1_fn_3_Fig2_HTML.jpg https://docrohan.wordpress.com/wp-content/uploads/2013/06/multifocal-vs-multicentric.png?w=640

Previous Studies

- van Deurzen (2016)
 - Included all patients with invasive breast cancer (IBC)
 - Excluded DCIS, IBC after previous treatment
- Lombardi et al. (2019)
 - Included patients with early breast cancer clinically N0, who underwent BCS and sentinel lymph node biopsy
 - Excluded mastectomy, DCIS, neoadjuvant therapy
- Hotsinpiller et al. (2021)
 - Included patients with non-metastatic invasive breast cancer, who underwent BCS
 - Excluded radiation before surgery, unknown margin status, male breast cancer





Previous Studies

- Similarities:
 - Lobular histology, multifocality, tumor size
- Differences:
 - Age, ER+, grade, HER2/neu+, mixed histology
- Didn't Assess:
 - Angioinvasion, lymph node status, lympho-vascular invasion, presence/extent of DCIS, surgical technique (oncoplastic)
- Novel Findings:
 - Arrhythmia, 6 o'clock position





Conclusions

Positive margins were associated with recurrence (local + distant) but were <u>not</u> associated with overall survival.

The results of this study may help to guide surgeons and oncologists in the management of localized, invasive breast cancer

- 1) In planning appropriate surgeries based on tumor histology, focality, and breast location
- 2) In emphasizing timely follow-up in higher risk patients
- 3) In the education of patients regarding their care





References

- Bundred JR, Michael S, Stuart B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. *BMJ*. 2022;378:e070346. Published 2022 Sep 21. doi:10.1136/bmj-2022-070346
- CDC. CDC basic information about breast cancer. CDC. Published 2019. https://www.cdc.gov/cancer/breast/basic_info/index.htm
- Fregatti P, Gipponi M, Atzori G, et al. The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. *In Vivo*. 2022;36(2):814-820. doi:10.21873/invivo.12768
- Hotsinpiller WJ, Everett AS, Richman JS, Parker C, Boggs DH. Rates of margin positive resection with breast conservation for invasive breast cancer using the NCDB. *Breast*. 2021;60:86-89. doi:10.1016/j.breast.2021.08.012
- Lombardi A, Pastore E, Maggi S, et al. Positive margins (R1) risk factors in breast cancer conservative surgery. *Breast Cancer (Dove Med Press)*. 2019;11:243-248. Published 2019 Jul 26. doi:10.2147/BCTT.S210788
- Mootz A, Arjmandi F, Dogan BE, Evans WP. Health Care Disparities in Breast Cancer: The Economics of Access to Screening, Diagnosis, and Treatment. J Breast Imaging. 2020;2(6):524-529. doi:10.1093/jbi/wbaa093
- Shockney L. Breast Cancer Facts & Statistics for 2022. National Breast Cancer Foundation. Published June 2023. https://www.nationalbreastcancer.org/breast-cancer-facts/
- van Deurzen CH. Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study. *Ann Surg Oncol.* 2016;23(Suppl 5):627-633. doi:10.1245/s10434-016-5532-5
- World Health Organization. Breast cancer. www.who.int. Published March 13, 2024. https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=In%202022%2C%20there%20ere%202.3





Questions?







Institute for Academic Medicine Vandalia Health

